Cannabix Technologies to Beta Test Marijuana Breathalyzer with Occupational Health Clinic in Southern California to Meet Work...
November 23 2020 - 8:45AM
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the
“Company or Cannabix”) developer of the Cannabix Marijuana
Breathalyzer for law enforcement and the workplace, is pleased to
report that it plans to begin beta testing its version 3.0 THC
Breath Analyzer (“THCBA”) in southern California with an
occupational health care provider located in Newport Beach.
Cannabix expects to deliver its latest version of the THCBA to
Alipour Medical Centre early in the new year. Alipour Medical
Centre provides drug and alcohol testing services to a number of
local employers in the state. The THCBA is an ideal device for
employers and other markets who are seeking a way to quickly,
easily and non-invasively test for recent use of
∆9-tetrahydrocannabinol (“THC”) - the psychoactive component of
marijuana that causes impairment. Cannabix will be seeking
additional organizations for beta testing and welcomes interested
parties to contact us via our website (cannabixtechnologies.com).
Employers everywhere are struggling with the limitations of
current drug testing technology in identifying recent use of
marijuana that may be causing impairment during work hours and
differentiating this from recreational and medical use during
nonwork hours/days.
The Cannabix device allows for more relevant THC detection from
breath allowing employers to create an onsite regiment whereby they
can perform pre-access testing for recent use of marijuana before
and during work hours, instead of testing for drug use when
employees are not at work. Cannabix will be beta testing its device
in order to continue training the device’s machine learning
database and improve user experience through testing feedback. The
THCBA has been built to provide easy to understand screen prompts
for the positive and negative detection of THC in breath in a
portable manner, and can be administered without extensive
training.
Current forms of testing for marijuana use can identify THC
ranging from minutes to days prior to actual use, making it
impossible to show the difference between the two. Studies¹
have shown that breath is a better indicator of impairment than
saliva, blood, or urine because THC is present in breath for a
relatively short period of time (1-3 hours); whereas, it is
excreted at detectable levels in other body fluids for many hours,
days, or even weeks after smoking. This short time period of
detection in breath aligns with the peak impairment
window.
Dr. Nima Alipour, CEO of Alipour Medical Corp, stated, “We are
very pleased to be using one of the world’s first marijuana
breathalyzers in our medical facility. We know first-hand how the
legalization of marijuana has affected employers in our
state. As occupational health practitioners based in Orange
County, we understand the challenges that employers are facing in
providing relevant drug testing for existing and new
employees. We advise corporations on how best to
keep their workforce safe; identifying safety
issues as they pertain to impairment, while taking
into account employee rights in an environment of state
legalization. Alipour Medical prides itself on deploying
cutting edge technology in our practice and we look forward to
helping with research, and ultimately beta testing devices
alongside Cannabix Technologies in California.”
Parties interested in working with Cannabix to beta-test its
Cannabix Marijuana Breathalyzer are encouraged to contact the
Company at info@cannabixtechnologies.com
(1) Olla P, Ishraque MT, Bartol S. 2020. Evaluation of Breath
and Plasma Tetrahydrocannabinol Concentration Trends Postcannabis
Exposure in Medical Cannabis Patients. Cannabis and Cannabinoid
Res.; 99-104. Himes S. et al. 2013. Cannabinoids in Exhaled
Breath following Controlled Administration of Smoked Cannabis.
Clinical Chemistry; 1780–1789. Beck O, Sandqvist S, Dubbelboer
I, Franck J. 2011. Detection of delta9-tetrahydrocannabinol in
exhaled breath collected from cannabis users. J Anal Toxicol;
35:541– 4.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a leader in marijuana breathalyzer
development for law enforcement and the workplace. Cannabix has
established breath testing technologies in the pursuit of bringing
accurate, durable, portable tools to market to enable detection of
marijuana-impaired driving offences on roads at a time when
marijuana is becoming legal in many global jurisdictions. Cannabix
is working to develop drug-testing devices that will detect THC-
the psychoactive component of marijuana that causes intoxication-
using breath samples. In particular, Cannabix is focused on
developing breath testing devices for detection of recent use of
THC, in contrast to urine testing for THC metabolite that requires
an invasive collection and reflects usage, days or even weeks
earlier. The devices will also be useful for other practical
applications such as testing employees in the workplace where
impairment by THC can be hazardous.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEOCannabix Technologies Inc.
For further information, contact the Company at
info@cannabixtechnologies.com
The CSE has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking StatementsThis
press release contains forward-looking information that involves
various risks and uncertainties regarding future events. Such
forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company’s plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing “patent pending” technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Apr 2023 to Apr 2024